Literature DB >> 19249009

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Simon C Warby1, Alexandre Montpetit, Anna R Hayden, Jeffrey B Carroll, Stefanie L Butland, Henk Visscher, Jennifer A Collins, Alicia Semaka, Thomas J Hudson, Michael R Hayden.   

Abstract

Huntington disease (HD) is an autosomal-dominant disorder that results from >or=36 CAG repeats in the HD gene (HTT). Approximately 10% of patients inherit a chromosome that underwent CAG expansion from an unaffected parent with <36 CAG repeats. This study is a comprehensive analysis of genetic diversity in HTT and reveals that HD patients of European origin (n = 65) have a significant enrichment (95%) of a specific set of 22 tagging single nucleotide polymorphisms (SNPs) that constitute a single haplogroup. The disease association of many SNPs is much stronger than any previously reported polymorphism and was confirmed in a replication cohort (n = 203). Importantly, the same haplogroup is also significantly enriched (83%) in individuals with 27-35 CAG repeats (intermediate alleles, n = 66), who are unaffected by the disease, but have increased CAG tract sizes relative to the general population (n = 116). These data support a stepwise model for CAG expansion into the affected range (>or=36 CAG) and identifies specific haplogroup variants in the general population associated with this instability. The specific variants at risk for CAG expansion are not present in the general population in China, Japan, and Nigeria where the prevalence of HD is much lower. The current data argue that cis-elements have a major predisposing influence on CAG instability in HTT. The strong association between specific SNP alleles and CAG expansion also provides an opportunity of personalized therapeutics in HD where the clinical development of only a small number of allele-specific targets may be sufficient to treat up to 88% of the HD patient population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249009      PMCID: PMC2668007          DOI: 10.1016/j.ajhg.2009.02.003

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  90 in total

Review 1.  The contribution of cis-elements to disease-associated repeat instability: clinical and experimental evidence.

Authors:  J D Cleary; C E Pearson
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

2.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.

Authors:  Sudhir Kumar; Koichiro Tamura; Masatoshi Nei
Journal:  Brief Bioinform       Date:  2004-06       Impact factor: 11.622

3.  AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Authors:  Nicholas R Franich; Helen L Fitzsimons; Dahna M Fong; Matthias Klugmann; Matthew J During; Deborah Young
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

4.  Huntington's disease: genetic heterogeneity in black African patients.

Authors:  D S Magazi; A Krause; V Bonev; M Moagi; Z Iqbal; M Dludla; C H van der Meyden
Journal:  S Afr Med J       Date:  2008-03

5.  Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract.

Authors:  Christina L Liquori; Yoshio Ikeda; Marcy Weatherspoon; Kenneth Ricker; Benedikt G H Schoser; Joline C Dalton; John W Day; Laura P W Ranum
Journal:  Am J Hum Genet       Date:  2003-09-22       Impact factor: 11.025

6.  Allele-specific silencing of mutant Huntington's disease gene.

Authors:  Yu Zhang; Joshua Engelman; Robert M Friedlander
Journal:  J Neurochem       Date:  2009-01       Impact factor: 5.372

Review 7.  Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease.

Authors:  Cynthia T McMurray
Journal:  DNA Repair (Amst)       Date:  2008-05-09

8.  Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.

Authors:  P H J van Bilsen; L Jaspers; M S Lombardi; J C E Odekerken; E N Burright; W F Kaemmerer
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

9.  Molecular analysis of Huntington's disease and linked polymorphisms in the Indian population.

Authors:  Q Saleem; S Roy; U Murgood; R Saxena; I C Verma; A Anand; U Muthane; S Jain; S K Brahmachari
Journal:  Acta Neurol Scand       Date:  2003-10       Impact factor: 3.209

10.  CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination.

Authors:  Randell T Libby; Katharine A Hagerman; Victor V Pineda; Rachel Lau; Diane H Cho; Sandy L Baccam; Michelle M Axford; John D Cleary; James M Moore; Bryce L Sopher; Stephen J Tapscott; Galina N Filippova; Christopher E Pearson; Albert R La Spada
Journal:  PLoS Genet       Date:  2008-11-14       Impact factor: 5.917

View more
  76 in total

Review 1.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype.

Authors:  Gunnar Houge; Ove Bruland; Inga Bjørnevoll; Michael R Hayden; Alicia Semaka
Journal:  Neurology       Date:  2013-08-14       Impact factor: 9.910

4.  Response to Falush: a role for cis-element polymorphisms in HD.

Authors:  Simon C Warby; Henk Visscher; Stefanie Butland; Christopher E Pearson; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

5.  Haplotype background, repeat length evolution, and Huntington's disease.

Authors:  Daniel Falush
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

Review 6.  CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Authors:  Douglas R Langbehn; Michael R Hayden; Jane S Paulsen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

7.  Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.

Authors:  Miguel A Varela; Helen J Curtis; Andrew G L Douglas; Suzan M Hammond; Aisling J O'Loughlin; Maria J Sobrido; Janine Scholefield; Matthew J A Wood
Journal:  Eur J Hum Genet       Date:  2015-05-20       Impact factor: 4.246

Review 8.  Repeat instability during DNA repair: Insights from model systems.

Authors:  Karen Usdin; Nealia C M House; Catherine H Freudenreich
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-01-22       Impact factor: 8.250

9.  A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.

Authors:  Chris Kay; Jennifer A Collins; Nicholas S Caron; Luciana de Andrade Agostinho; Hailey Findlay-Black; Lorenzo Casal; Dulika Sumathipala; Vajira H W Dissanayake; Mario Cornejo-Olivas; Fiona Baine; Amanda Krause; Jacquie L Greenberg; Carmen Lúcia Antão Paiva; Ferdinando Squitieri; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2019-11-07       Impact factor: 11.025

Review 10.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.